NASDAQ:PEAR Pear Therapeutics (PEAR) Stock Forecast, Price & News Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume125 shsAverage Volume7.75 million shsMarket Capitalization$4.17 millionP/E RatioN/ADividend YieldN/APrice Target$6.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Pear Therapeutics MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside∞ Upside$6.67 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.85) to ($0.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.74 out of 5 stars 3.1 Analyst's Opinion Consensus RatingPear Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.67, Pear Therapeutics has a forecasted upside of ∞ from its current price of $0.00.Amount of Analyst CoveragePear Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PEAR. Previous Next 0.0 Dividend Strength Dividend YieldPear Therapeutics does not currently pay a dividend.Dividend GrowthPear Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PEAR. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Pear Therapeutics this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pear Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders30.70% of the stock of Pear Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.17% of the stock of Pear Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Pear Therapeutics are expected to grow in the coming year, from ($0.85) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pear Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pear Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Pear Therapeutics (NASDAQ:PEAR) StockPear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.Read More PEAR Stock News HeadlinesSeptember 25, 2023 | finance.yahoo.comPear Therapeutics, Inc. (PEARQ)September 14, 2023 | axios.comADHD video game maker Akili shifts focus from prescription to OTC, lays off 40%September 28, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 13, 2023 | bizjournals.comDigital health startup Akili cuts staff by 40%, abandons prescription modelAugust 28, 2023 | benzinga.comShaping the Future of Medicine: Anticipated $17.7 Billion Digital Therapeutics Market by 2027August 23, 2023 | msn.comFormer execs from defunct Pear Therapeutics start VC firmJuly 27, 2023 | msn.comStartups Struggle With Insurers Over Digital TreatmentsJuly 3, 2023 | bizjournals.comBiotech layoffs 2023: In Q2, more than 700 Boston-area life science jobs were cutSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsJune 26, 2023 | forbes.comPrescription Digital Therapeutics For Mental Health: What It Means For Doctors And Their PatientsJune 22, 2023 | marketwatch.comDigital Therapeutics (DTx) Market Research Report 2023 Future Opportunities, Latest Trends, In-depth Analysis, and Forecast To 2030June 20, 2023 | finance.yahoo.comNox Health Closes Acquisition of Somryst, the Only FDA-Cleared Digital Insomnia Treatment, From Pear TherapeuticsJune 12, 2023 | bizjournals.comBehaVR adds 3 executives to senior leadership teamJune 8, 2023 | finance.yahoo.comGlobal Digital Therapeutics [DTx] for Mental Health Market SizeJune 8, 2023 | finance.yahoo.comBehaVR Appoints Former Pear Therapeutics, TytoCare and AVIA Executives to Senior Leadership TeamMay 22, 2023 | axios.comPear Therapeutics sold for partsMay 16, 2023 | marketwatch.comDigital Therapeutics Market 2023 Industry Trends, Growth, Size, Segmentation, Opportunities and Revenue by Forecast to 2031May 14, 2023 | markets.businessinsider.comChardan Capital Reaffirms Their Buy Rating on Orchestra BioMed Holdings (OBIO)May 9, 2023 | markets.businessinsider.comSeres Therapeutics (MCRB) Gets a Buy from Chardan CapitalMay 9, 2023 | investing.comPear Therapeutics Inc (PEARQ)May 5, 2023 | markets.businessinsider.comChardan Capital Remains a Buy on Omega Therapeutics (OMGA)May 4, 2023 | markets.businessinsider.comChardan Capital Sticks to Its Buy Rating for Alnylam Pharma (ALNY)May 3, 2023 | wsj.comFirm Retention Summary: Pear TherapeuticsApril 29, 2023 | marketwatch.comDigital Therapeutics (DTx) Market Growth Strategies, Size, Geography Trends and Competitive Analysis to 2030April 17, 2023 | finance.yahoo.comIt's Down 82% But Pear Therapeutics, Inc. (NASDAQ:PEAR) Could Be Riskier Than It LooksApril 14, 2023 | msn.comWhy Navidea Biopharmaceuticals Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving PremarketApril 14, 2023 | msn.comWhy Is Pear Therapeutics (PEAR) Stock Down 26% Today?See More Headlines Receive PEAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pear Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PEAR Company Calendar Today9/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Health services Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PEAR CUSIPN/A CIK1835567 Webpeartherapeutics.com Phone617-925-7848FaxN/AEmployees300Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.67 High Stock Price Forecast$8.00 Low Stock Price Forecast$5.00 Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,490,000.00 Net Margins-594.70% Pretax Margin-594.70% Return on Equity-217.85% Return on Assets-95.20% Debt Debt-to-Equity RatioN/A Current Ratio1.48 Quick Ratio1.48 Sales & Book Value Annual Sales$12.69 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / BookN/AMiscellaneous Outstanding Shares142,739,000Free Float98,918,000Market Cap$4.17 million OptionableNot Optionable Beta0.45 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Corey M. McCann M.D. (Age 43)Ph.D., Founder, Pres, CEO & Director Comp: $702.45kMr. Christopher D. T. Guiffre J.D. (Age 55)M.B.A., MBA, CFO, COO, Treasurer & Assistant Sec. Comp: $564.37kMs. Julia M. Strandberg M.B.A. (Age 48)Chief Commercial Officer Comp: $582.43kMr. Ronan P. O'Brien J.D. (Age 50)Chief Compliance Officer, Gen. Counsel & Sec. Ms. Meara MurphySr. Director of Corp. CommunicationsDr. Yuri Maricich M.B.A. (Age 43)M.D., Chief Medical Officer & Head of Devel. Mr. Chris Valosky M.B.A.VP of SalesMs. Katherine Jeffery M.Sc. (Age 56)Chief People Officer Ms. Erin K. Brenner (Age 50)Chief Product Devel. Officer Ms. Ellen E. Snow CPA (Age 50)CGMA, VP & Corp. Controller More ExecutivesKey CompetitorsBetter TherapeuticsNASDAQ:BTTXCyclacel PharmaceuticalsNASDAQ:CYCCZyVersa TherapeuticsNASDAQ:ZVSAQuoin PharmaceuticalsNASDAQ:QNRXGraybug VisionNASDAQ:GRAYView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 200 shares on 8/4/2023Ownership: 0.000%5Am Partners Iv, LlcSold 16,544,113 sharesTotal: $1.99 M ($0.12/share)Corey MccannSold 34,731 sharesTotal: $39,246.03 ($1.13/share)Christopherd T GuiffreSold 19,540 sharesTotal: $22,080.20 ($1.13/share)Ellen SnowSold 8,027 sharesTotal: $9,070.51 ($1.13/share)View All Insider TransactionsView All Institutional Transactions PEAR Stock - Frequently Asked Questions Should I buy or sell Pear Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pear Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PEAR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PEAR, but not buy additional shares or sell existing shares. View PEAR analyst ratings or view top-rated stocks. What is Pear Therapeutics' stock price forecast for 2023? 4 equities research analysts have issued twelve-month target prices for Pear Therapeutics' stock. Their PEAR share price forecasts range from $5.00 to $8.00. On average, they predict the company's stock price to reach $6.67 in the next twelve months. View analysts price targets for PEAR or view top-rated stocks among Wall Street analysts. What is Pear Therapeutics' stock symbol? Pear Therapeutics trades on the NASDAQ under the ticker symbol "PEAR." Who are Pear Therapeutics' major shareholders? Pear Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.00%). Insiders that own company stock include 5Am Partners Iv, Llc, Christopherd T Guiffre, Corey Mccann, Ellen Snow and Ronan O'brien. View institutional ownership trends. How do I buy shares of Pear Therapeutics? Shares of PEAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. How much money does Pear Therapeutics make? Pear Therapeutics (NASDAQ:PEAR) has a market capitalization of $0.00 and generates $12.69 million in revenue each year. The company earns $-75,490,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. How many employees does Pear Therapeutics have? The company employs 300 workers across the globe. How can I contact Pear Therapeutics? Pear Therapeutics' mailing address is 195 CHURCH STREET 15TH FLOOR, NEW HAVEN CT, 06510. The official website for the company is peartherapeutics.com. The company can be reached via phone at 617-925-7848 or via email at meara.murphy@peartherapeutics.com. This page (NASDAQ:PEAR) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pear Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.